No Data
Here's Why Shandong Jincheng Pharmaceutical Group (SZSE:300233) Can Manage Its Debt Responsibly
Shandong Jincheng Pharmaceutical Group (300233.SZ) special dividend plan: proposed to distribute 1.5 yuan for every 10 shares.
Gelonghui, January 17 - Shandong Jincheng Pharmaceutical Group (300233.SZ) announced the special dividend plan. The company intends to use the total share capital of 379,331,587 shares, after deducting the repurchased shares from the company's repurchase account (the total share capital is 383,874,587 shares, with 4,543,000 shares deducted), to distribute a cash dividend of 1.5 yuan (including tax) for every 10 shares to all shareholders registered on the equity registration date, totaling 56.8997 million yuan (including tax). In addition to the aforementioned cash dividend, no bonus shares will be distributed in this profit distribution.
Shandong Jincheng Pharmaceutical Group (300233.SZ): The terminal formulation product Oseltamivir phosphate can be used to treat or prevent influenza A and B.
On January 6, 2023, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that the company produces and sells Oseltamivir phosphate Active Pharmaceutical Ingredient. Its terminal formulation product Oseltamivir phosphate can be used for the treatment or prevention of Influenza A and B.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Currently, the company's astaxanthin products are mainly applied in fields such as aquaculture and agricultural fertilizers.
On December 23, Glonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that its astaxanthin products are currently mainly applied in fields such as aquaculture and fertilizers.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Jinsuo injectable Cefoperazone Sodium and Sulbactam Sodium has obtained the approval notification for the Pharmaceutical supplementary application.
On December 20, Glonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its holding subsidiary Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd. (hereinafter referred to as "Jincheng Jinsuo") has recently received the approval notice for the supplementary application of injectable cefoperazone sodium and sulbactam sodium from the National Medical Products Administration (Certificate No.: 2024B05973, 2024B05974). Upon review, this product has passed the consistency evaluation for the quality and efficacy of generic drugs. This product is suitable for treating infections of the upper and lower respiratory tract caused by sensitive bacteria; upper and lower urinary tract infections; peritonitis, cholecystitis, cholangitis and Other abdominal infections.
Further Weakness as Shandong Jincheng Pharmaceutical Group (SZSE:300233) Drops 8.2% This Week, Taking Three-year Losses to 50%
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
